
Clinuvel Pharmaceuticals Limited: shareholders and insiders
Price
$4.66
November 20, 2026Market cap $235M
What Ploutos Investor adds for Clinuvel Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from FY2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by Clinuvel Pharmaceuticals's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
No filing over 5%
Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for Clinuvel Pharmaceuticals shares.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
No well-known manager
None of the managers we track held Clinuvel Pharmaceuticals shares in their latest 13F.
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 20.2% of the shares in the reported trades were short sales, against 23.9% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 20.2%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 23.9%
- Change
- -3.7 pts
- Short sales a dayon average, of 2,565 shares
- 518
- More than atof 3,666 US-listed companies, same days
- 1%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 61.5%
- Oct 14, 2026: Short sales 8.8%
- Oct 15, 2026: Short sales 35.7%
- Oct 16, 2026: Short sales 20.9%
- Oct 19, 2026: Short sales 19.7%
- Oct 20, 2026: Short sales 0.9%
- Oct 21, 2026: Short sales 28.9%
- Oct 22, 2026: Short sales 44.6%
- Oct 23, 2026: Short sales 13.8%
- Oct 26, 2026: Short sales 2.8%
- Oct 27, 2026: Short sales 0.5%
- Oct 28, 2026: Short sales 50.5%
- Oct 29, 2026: Short sales 19%
- Oct 30, 2026: Short sales 28.1%
- Nov 2, 2026: Short sales 3.5%
- Nov 3, 2026: Short sales 58.8%
- Nov 4, 2026: Short sales 4.1%
- Nov 5, 2026: Short sales 5.1%
- Nov 6, 2026: Short sales 45.2%
- Nov 9, 2026: Short sales 53.9%
- Nov 10, 2026: Short sales 35.5%
- Nov 11, 2026: Short sales 6.2%
- Nov 12, 2026: Short sales 11.1%
- Nov 13, 2026: Short sales 25.1%
- Nov 16, 2026: Short sales 3.2%
- Nov 17, 2026: Short sales 53.9%
- Nov 18, 2026: Short sales 17.9%
- Nov 19, 2026: Short sales 11.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- VSSVanguard Ftse All-World Ex-Us Small-Cap Index FundWeight in the fund0.01%
- VPLVanguard Pacific Stock Index FundWeight in the fund0.00%
- DFICDimensional International Core Equity 2 ETFWeight in the fund0.00%
- VEAVanguard Developed Markets Index FundWeight in the fund0.00%
- DFAIDimensional International Core Equity Market ETFWeight in the fund0.00%
- VXUSVanguard Total International Stock Index FundWeight in the fund0.00%
- DFAXDimensional World ex. U.S. Core Equity 2 ETFWeight in the fund0.00%
- VTVanguard Total World Stock Index FundWeight in the fund0.00%
- SPDWState Street(R) SPDR(R) Portfolio Developed World ex-US ETFWeight in the fund0.00%
9 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q1 2015: Managers 1
- Q2 2015: Managers 1
- Q3 2015: Managers 1
- Q2 2019: Managers 1
Institutional investors by quarter
The fund managers holding CUVL, quarter by quarter, from Q3 2014 to Q4 2014, 2 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 6 quarters.
Q2 2019: 1 managers held 9,000 shares, worth $215M. During the quarter 1 opened a position, 0 closed one, 0 added and 0 trimmed.
From the SEC's Form 13F data sets, Q1 2015 to Q2 2019: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Clinuvel Pharmaceuticals's filings show?
Who buys and sells is one part of Clinuvel Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have CUVL's insiders bought or sold?
From – to – Clinuvel Pharmaceuticals's insiders reported no purchase or sale of shares on the market.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.